Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Wet Macular Degeneration Treatment Pipeline Review H2 2016

Monday, October 10, 2016 6:01
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Review, H2 2016’, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/649773-wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration 
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects 
- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Request a sample report @ https://www.wiseguyreports.com/sample-request/649773-wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/649773-wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2016

Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 6 
List of Figures 8 
Introduction 9 
Global Markets Direct Report Coverage 9 
Wet (Neovascular / Exudative) Macular Degeneration Overview 10 
Therapeutics Development 11 
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration – Overview 11 
Wet (Neovascular / Exudative) Macular Degeneration – Therapeutics under Development by Companies 12 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline Products Glance 16 
Late Stage Products 16 
Clinical Stage Products 17 
Early Stage Products 18 
Wet (Neovascular / Exudative) Macular Degeneration – Products under Development by Companies 19 
Wet (Neovascular / Exudative) Macular Degeneration – Companies Involved in Therapeutics Development 25 
Aciont Inc. 25 
Adverum Biotechnologies, Inc. 26 
Allergan Plc 27 
Alteogen Inc. 28 
Amakem NV 29 
Ampio Pharmaceuticals, Inc. 30 
Apellis Pharmaceuticals, Inc. 31 
Apexigen, Inc. 32 
Applied Genetic Technologies Corporation 33 
Benitec Biopharma Limited 34 
Boehringer Ingelheim GmbH 35 
Cell Medica Limited 36 
Charlesson LLC. 37 
Cipla Ltd. 38 
Clanotech AB 39 
Clearside BioMedical, Inc. 40 
Clonz Biotech Private Limited 41 
Coherus BioSciences, Inc. 42 
Daiichi Sankyo Company, Limited 43 
Diffusion Pharmaceuticals Inc. 44 
Eleven Biotherapeutics Inc. 45 
Exonate Limited 46 
F. Hoffmann-La Roche Ltd. 47 
Formycon AG 48 
Graybug Vision Inc 49 
GTx, Inc. 50 
iCo Therapeutics Inc. 51 
Icon Bioscience, Inc. 52 
Iconic Therapeutics, Inc. 53 
Kala Pharmaceuticals, Inc. 54 
Kodiak Sciences Inc. 55 
Mabion SA 56 
MeiraGTx Limited 57 
Mitotech S.A. 58 
Ocular Therapeutix, Inc. 59 
Ohr Pharmaceutical Inc. 60 
Ophthotech Corp. 61 
Oxford BioMedica Plc 62 
PanOptica, Inc. 63 
Pfenex Inc. 64 
Pfizer Inc. 65 
pSivida Corp. 66 
Regeneron Pharmaceuticals Inc 67 
RegenxBio Inc. 68 
RXi Pharmaceuticals Corporation 69 
Santen Pharmaceutical Co., Ltd. 70 
Sanwa Kagaku Kenkyusho Co., Ltd. 71 
TRACON Pharmaceuticals, Inc. 72 
TWi Pharmaceuticals, Inc. 73 
Tyrogenex, Inc. 74 
Xbrane Biopharma AB 75 
Wet (Neovascular / Exudative) Macular Degeneration – Therapeutics Assessment 76 
Assessment by Monotherapy Products 76 
Assessment by Combination Products 77 
Assessment by Target 78 
Assessment by Mechanism of Action 81 
Assessment by Route of Administration 85 
Assessment by Molecule Type 87 
Drug Profiles 89 
(aflibercept + nesvacumab) – Drug Profile 89 
(aflibercept + rinucumab) – Drug Profile 90 
A-006 – Drug Profile 91 
abicipar pegol – Drug Profile 92 
AC-301 – Drug Profile 95 
ACX-107 – Drug Profile 96 
aflibercept – Drug Profile 97 
aflibercept biosimilar – Drug Profile 106 
aflibercept biosimilar – Drug Profile 107 
AGN-151200 – Drug Profile 108 
ALG-1001 – Drug Profile 110 
AMA-0428 – Drug Profile 113 
APL-2 – Drug Profile 114 
APX-003 – Drug Profile 116 
APX-3330 – Drug Profile 117 
AVA-101 – Drug Profile 119 
AVA-201 – Drug Profile 122 
avacincaptad pegol sodium – Drug Profile 123 
axitinib – Drug Profile 125 
AXT-108 – Drug Profile 127 
bertilimumab – Drug Profile 128 
Beta-LGND2 – Drug Profile 132 
BI-144807 – Drug Profile 134 
brolucizumab – Drug Profile 135 
C-16Y – Drug Profile 137 
CBT-128 – Drug Profile 138 
CLT-005 – Drug Profile 139 
CLT-28643 – Drug Profile 140 
cyclosporine – Drug Profile 141 
DA-3131 – Drug Profile 142 
danazol – Drug Profile 143 
DE-120 – Drug Profile 147 
DNX-214 – Drug Profile 148 
Doxarubicin Pegylated – Drug Profile 149 
Drug for Age Related Macular Degeneration – Drug Profile 150 
DS-7080 – Drug Profile 151 
ENV-1305 – Drug Profile 152 
GB-101 – Drug Profile 153 
Gene Therapy 1 for Wet Age-Related Macular Degeneration – Drug Profile 154 
Gene Therapy for Wet Age-related Macular Degeneration – Drug Profile 155 
hI-con1 – Drug Profile 156 
IVMED-50 – Drug Profile 158 
IVMED-55 – Drug Profile 159 
K-106 – Drug Profile 160 
KSI-201 – Drug Profile 161 
LHA-510 – Drug Profile 162 
Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration – Drug Profile 163 
OCU-200 – Drug Profile 164 
OLX-301 – Drug Profile 165 
ONL-1204 – Drug Profile 166 
OPT-302 – Drug Profile 167 
OXB-201 – Drug Profile 171 
PAN-90806 – Drug Profile 173 
pegpleranib sodium – Drug Profile 175 
PF-05206388 – Drug Profile 178 
PF-655 – Drug Profile 180 
plastoquinone decyl triphenylphosphonium bromide – Drug Profile 182 
Protein to Inhibit VEGF for Wet Age Related Macular Degeneration – Drug Profile 184 
ranibizumab – Drug Profile 185 
ranibizumab biosimilar – Drug Profile 191 
ranibizumab biosimilar – Drug Profile 192 
ranibizumab biosimilar – Drug Profile 193 
ranibizumab biosimilar – Drug Profile 195 
ranibizumab biosimilar – Drug Profile 196 
ranibizumab biosimilar – Drug Profile 197 
ranibizumab biosimilar – Drug Profile 198 
Recombinant Protein for Age Related Macular Degeneration – Drug Profile 199 
Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration – Drug Profile 200 
RES-529 – Drug Profile 201 
RG-7716 – Drug Profile 205 
RGX-314 – Drug Profile 206 
RXI-109 – Drug Profile 208 
SK-1011 – Drug Profile 214 
Small Molecule for Wet AMD and Dry AMD – Drug Profile 215 
Small Molecules for Dry and Wet Age Related Macular Degeneration – Drug Profile 216 
Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration – Drug Profile 217 
SPHINX-31 – Drug Profile 218 
squalamine lactate – Drug Profile 219 
sunitinib malate – Drug Profile 227 
Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration – Drug Profile 229 
TRC-105 – Drug Profile 230 
triamcinolone acetonide – Drug Profile 238 
TT-211 – Drug Profile 239 
TT-231 – Drug Profile 240 
X-82 – Drug Profile 241 
Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects 244 
Wet (Neovascular / Exudative) Macular Degeneration – Discontinued Products 248 
Wet (Neovascular / Exudative) Macular Degeneration – Product Development Milestones 249 
Featured News & Press Releases 249 
Appendix 259 
Methodology 259 
Coverage 259 
Secondary Research 259 
Primary Research 259 
Expert Panel Validation 259 
Contact Us 259 
Disclaimer 260List of Tables 
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016 18 
Number of Products under Development by Companies, H2 2016 19 
Number of Products under Development by Companies, H2 2016 (Contd..1) 20 
Number of Products under Development by Companies, H2 2016 (Contd..2) 21 
Number of Products under Development by Companies, H2 2016 (Contd..3) 22 
Comparative Analysis by Late Stage Development, H2 2016 23 
Comparative Analysis by Clinical Stage Development, H2 2016 24 
Comparative Analysis by Early Stage Development, H2 2016 25 
Products under Development by Companies, H2 2016 26 
Products under Development by Companies, H2 2016 (Contd..1) 27 
Products under Development by Companies, H2 2016 (Contd..2) 28 
Products under Development by Companies, H2 2016 (Contd..3) 29 
Products under Development by Companies, H2 2016 (Contd..4) 30 
Products under Development by Companies, H2 2016 (Contd..5) 31 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Aciont Inc., H2 2016 32 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Adverum Biotechnologies, Inc., H2 2016 33 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Allergan Plc, H2 2016 34 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Alteogen Inc., H2 2016 35 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Amakem NV, H2 2016 36 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 37 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Apellis Pharmaceuticals, Inc., H2 2016 38 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Apexigen, Inc., H2 2016 39 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Applied Genetic Technologies Corporation, H2 2016 40 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Benitec Biopharma Limited, H2 2016 41 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Boehringer Ingelheim GmbH, H2 2016 42 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Cell Medica Limited, H2 2016 43 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Charlesson LLC., H2 2016 44 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Cipla Ltd., H2 2016 45 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Clanotech AB, H2 2016 46 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Clearside BioMedical, Inc., H2 2016 47 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Clonz Biotech Private Limited, H2 2016 48 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Coherus BioSciences, Inc., H2 2016 49 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 50 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 51 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Eleven Biotherapeutics Inc., H2 2016 52 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Exonate Limited, H2 2016 53 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 54 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Formycon AG, H2 2016 55 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Graybug Vision Inc, H2 2016 56 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by GTx, Inc., H2 2016 57 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by iCo Therapeutics Inc., H2 2016 58 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Icon Bioscience, Inc., H2 2016 59 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Iconic Therapeutics, Inc., H2 2016 60 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Kala Pharmaceuticals, Inc., H2 2016 61 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Kodiak Sciences Inc., H2 2016 62 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Mabion SA, H2 2016 63 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by MeiraGTx Limited, H2 2016 64 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Mitotech S.A., H2 2016 65 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ocular Therapeutix, Inc., H2 2016 66 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ohr Pharmaceutical Inc., H2 2016 67 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Ophthotech Corp., H2 2016 68 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Oxford BioMedica Plc, H2 2016 69 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by PanOptica, Inc., H2 2016 70 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Pfenex Inc., H2 2016 71 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Pfizer Inc., H2 2016 72 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by pSivida Corp., H2 2016 73 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 74 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by RegenxBio Inc., H2 2016 75 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by RXi Pharmaceuticals Corporation, H2 2016 76 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 77
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 78 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by TRACON Pharmaceuticals, Inc., H2 2016 79 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by TWi Pharmaceuticals, Inc., H2 2016 80 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Tyrogenex, Inc., H2 2016 81 
Wet (Neovascular / Exudative) Macular Degeneration – Pipeline by Xbrane Biopharma AB, H2 2016 82 
Assessment by Monotherapy Products, H2 2016 83 
Assessment by Combination Products, H2 2016 84 
Number of Products by Stage and Target, H2 2016 86 
Number of Products by Stage and Mechanism of Action, H2 2016 89 
Number of Products by Stage and Route of Administration, H2 2016 93 
Number of Products by Stage and Molecule Type, H2 2016 95 
Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects, H2 2016 251 
Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects (Contd..1), H2 2016 252 
Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects (Contd..2), H2 2016 253 
Wet (Neovascular / Exudative) Macular Degeneration – Dormant Projects (Contd..3), H2 2016 254 
Wet (Neovascular / Exudative) Macular Degeneration – Discontinued Products, H2 2016 255List of Figures 
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H2 2016 18 
Number of Products under Development by Companies, H2 2016 19 
Comparative Analysis by Late Stage Development, H2 2016 23 
Comparative Analysis by Clinical Stage Development, H2 2016 24 
Comparative Analysis by Early Stage Products, H2 2016 25 
Assessment by Monotherapy Products, H2 2016 83 
Number of Products by Top 10 Targets, H2 2016 85 
Number of Products by Stage and Top 10 Targets, H2 2016 85 
Number of Products by Top 10 Mechanism of Actions, H2 2016 88 
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 88 
Number of Products by Top 10 Routes of Administration, H2 2016 92 
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 92 
Number of Products by Top 10 Molecule Types, H2 2016 94 
Number of Products by Stage and Top 10 Molecule Types, H2 2016 94

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649773

               

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.